Vildagliptin does not affect C-peptide clearance in patients with type 2 diabetes

Journal of Clinical Pharmacology

Volumn 47, Issue 1, 2007, Pages 127-131

  He, Yan Ling ^a   Horowitz, Anne ^b   Watson, Catherine E ^a   Foley, James E ^b   Sallas, William ^b   Ligueros Saylan, Monica ^b  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

C peptide; Type 2 diabetes; Vildagliptin

Indexed keywords

C PEPTIDE; PLACEBO; VILDAGLIPTIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RELEASE; MALE; MATHEMATICAL MODEL; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE;

ADAMANTANE; ADULT; ANALYSIS OF VARIANCE; ANTIGENS, CD26; BLOOD GLUCOSE; C-PEPTIDE; CHROMATOGRAPHY, LIQUID; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; RADIOIMMUNOASSAY; TANDEM MASS SPECTROMETRY; TIME FACTORS;

EID: 33845766209     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006295061     Document Type: Article

References (18)

1. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab. 1995 ; 80: 952-957.
2. Ahren B, Larsson H, Holst JJ. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1997 ; 82: 473-478.
3. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993 ; 91: 301-307.
4. Creutzfeldt WOC, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care. 1996 ; 19: 580-586.
5. Egan JM, Meneilly GS, Habener JF, Elahi D. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state. J Clin Endocrinol Metab. 2002 ; 87: 3768-3773.
6. Prigeon RL, Quddusi S, Paty B, D'Alessio DA. Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect. Am J Physiol: Endocrinol Metab. 2003 ; 285: E701 - E707.
7. Deacon CF, Ahren B, Holst JJ. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes? Expert Opinion Invest Drugs. 2004 ; 13: 1091-1102.
8. Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obesity Metab. 2005 ; 7: 692-698.
9. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Hormone Metab Res. 2006 ; 38: 423-428.
10. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 2004 ; 27: 2874-2880.
11. van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels: comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes. 1992 ; 41: 368-377.
12. Mentlein R. Dipeptidyl-peptidase IV (CD26): role in the inactivation of regulatory peptides. Regul Peptides. 1999 ; 85: 9-24.
13. Melani F, Rubenstein AH, Oyer PE, Steiner DF. Identification of proinsulin and C-peptide in human serum by a specific immunoassay. Proc Natl Acad Sci USA. 1970 ; 67: 148-155.
14. Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab. 2005 ; 90: 4888-4894.
15. Mari A, Tura A, Gastaldelli A, Ferrannini E. Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation. Diabetes. 2002 ; 51 (suppl 1). S221 - S226.
16. Villhauer EB, Brinkman JA, Naderi GB, et al. 1-[[(3-hydroxy-1- adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem. 2003 ; 46: 2774-2789.
17. He YL, Balch A, Campestrini J. Pharmacokinetics and pharmacodynamics of the DPP-4 inhibitor, LAF237, in patients with type 2 diabetes [abstract]. Clin Pharmacol Ther. 2005 ; 77: 56-56.
18. Ahren B, Landin-Olsson M, Jansson P-A, Svenson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab. 2004 ; 89: 2078-2084.